News from the healthcare data industry
Syapse will continue to identify, validate, and address discrepancies in real-world data, producing an accurate and fully contextualized narrative of a patient’s experience January 20, 2022 10:00 ET | Source: Syapse …...
Abstract Background: The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted...
BOSTON, Jan. 19, 2022 /PRNewswire/ — Analysis Group, a global leader in health economics and outcomes research (HEOR), announced that its groundbreaking method for generating real-world data (RWD) has proven both effective and...
Palo Alto, California, Jan. 19, 2022 (GLOBE NEWSWIRE) — Health Gorilla, leading Health Information Network in the United States, announced today their hiring of Carol Allis as Chief Compliance Officer....
REDMOND, Wash. and ATLANTA, Jan. 18, 2022 (GLOBE NEWSWIRE) — Truveta, the health system-led company with a vision of saving lives with data, and the Health Care business of LexisNexis...
Results validate company’s methodology and provide insight about the rapid evolution of future variants of concern January 18, 2022 08:45 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–nference, an AI-driven health...
TAMPA, Fla., Jan. 18, 2022 /PRNewswire/ — M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry leading data and analytics, today announced that it has expanded its executive team with the...
Data analytics company run by Paul Drayson says money could run out in weeks unless it finds emergency funding Julia KolleweFri 14 Jan 2022 13.55 EST Shares in Sensyne Health plummeted after...
SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ — Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, today announced a $150 million Series E...
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and...